Therapy of Hepatitis B and Prevention of Hepatocellular Carcinoma

  • Nancy Leung
Conference paper


Major advances have been made in the past two decades in the therapy of chronic hepatitis B. However, it is not clear whether these are truly “milestones” in our laborious quest to control HBV infection and to overcome this immense disease burden. The goals for therapy for chronic hepatitis B have been well defined: 1. Eradication of HBV from the host. 2. Resolution of inflammatory in the liver. 3. Prevent fibrosis and cirrhosis. 4. Prevention of HCC. 5. Restore survival and quality of life

In addressing these issues on therapy and prevention of HCC, one has to recognize a few important facts regarding CHB and HCC in Asian countries those are not seen in other parts of the world.


Chronic Hepatitis HBeAg Seroconversion Sustained Viral Response Lamivudine Therapy Lamivudine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 199: 172–80.Google Scholar
  3. 3.
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN. Extended lamivudine treatment in patients 83 with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17: 409–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-W, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–1263.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ. Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. J Clin Microbiol 2000; 38: 3205–8.PubMedGoogle Scholar
  8. 8.
    Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, Sung JJ. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol 2002; 97: 2629–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, Ching JY, Leung NW, Tam JS, Sung JJ. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 9: 406–12.CrossRefGoogle Scholar
  10. 10.
    Chien RN, Liaw YF, Atkins M, et al. Pretherapy alanine aminotransaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hapatitis B. Hepatology 1999; 30: 770–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD. Two sensitive PCR-based methods for the detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37: 3338–3347.PubMedGoogle Scholar
  12. 12.
    Stuvyer LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. The HEP DART International Committee. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751–757.CrossRefGoogle Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Nancy Leung
    • 1
  1. 1.Prince of Wales HospitalThe Chinese University of Hong KongHong Kong, China

Personalised recommendations